Dr. Lal Path Labs has incorporated a step-down subsidiary, Dr Lal PathLabs Indomed LLC, in Tashkent, Uzbekistan, to expand its diagnostic services footprint in Central Asia.

The incorporation was executed by Dr Lal PathLabs FZCO, a wholly owned subsidiary of Dr. Lal Path Labs based in Dubai, United Arab Emirates. On August 19, 2026, the Dubai entity agreed to subscribe to 70% of the share capital of the newly formed Tashkent-based company.

Subsidiary details

The key details of the corporate action are as follows:

The establishment of Dr Lal PathLabs Indomed LLC represents a strategic move by Dr. Lal Path Labs to extend its diagnostics presence beyond India into Uzbekistan. The subsidiary will be engaged in providing diagnostic services, aligning with the parent company’s core business line.

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023. As the entity is newly incorporated, turnover and size metrics are not applicable. No governmental or regulatory approvals are required for this acquisition.

Dr. Lal PathLabs reported a 27.2% year-on-year increase in consolidated net profit to ₹1,705 crore for the quarter ended June 30, 2026, driven by robust volume-led revenue growth and expanding operating margins. The diagnostics company’s total income from operations rose 18.9% to ₹8,296 crore, while EBITDA grew 28.7% to ₹2,564 crore, with margins improving to 30.9% from 28.7% in the previous year. The Board of Directors approved an interim dividend of ₹5 per equity share, payable to shareholders on record by July 30, 2026.

Financial Performance

The company demonstrated strong operational efficiency, with profit before tax rising 26.3% to ₹2,287 crore. Standalone results also reflected this upward trajectory, with standalone net profit increasing 28.3% to ₹1,659 crore. The growth was underpinned by higher sample volumes rather than price hikes, indicating sustained demand across its network. Basic earnings per share (EPS) stood at ₹10.15, up from ₹7.94 in Q1FY26.

Operational Highlights

Revenue growth was primarily volume-driven, with sample volumes increasing by 10.7% year-on-year and patient volumes rising by 8.2%. As of March 31, 2026, Dr. Lal PathLabs operated 312 clinical laboratories, 7,727 Patient Service Centers (PSCs), and 13,935 Pick-up Points (PUPs). The company serviced over 1 lakh patients through its rural outreach program in seven states during the quarter.

Strategic Acquisitions and ESOPs

Dr. Lal PathLabs expanded its international and technological footprint through two key acquisitions approved by its subsidiaries:

• Sunshine Healthcare Limited (Ghana): An 80% stake acquired for up to GHS 45.6 million (approx. ₹380 million) to strengthen presence in West Africa.
• Neuome Technologies Private Limited: A 30% stake acquired for up to ₹35 million to enhance pre-analytical technology capabilities.

Additionally, the Board approved the granting of 119,300 stock options under the Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 to eligible employees. The exercise price is set at the face value of ₹10 per share, with vesting occurring between one and four years from the grant date.

What the Numbers Show

The disproportionate growth in net profit (27.2%) compared to revenue (18.9%) highlights significant operating leverage. Group CFO Ved Goel attributed this to "disciplined execution" and an improved test mix. The acquisition of Shahbazkers Diagnostic Centre earlier in the quarter contributed to top-line growth, while cash reserves stood at ₹1,693 crore as of June 30, 2026. The company noted that it evaluates performance as a single unit, with no reportable segments under Ind AS 108.